Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Female Dyspareunia Clear all
Completed No phase listed Observational Results available

Laser Therapy for Treatment of Urogenital Symptoms in Women

NCT03681678
View directory record Official record
Conditions
Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina, Menopause Related Conditions, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Tract Infections, Stress Urinary Incontinence
Interventions
fCO2 Laser Therapy Group
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 9, 2026, 3:17 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
107
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting No phase listed Observational

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00499317
View directory record Official record
Conditions
Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS), Painful Bladder Syndrome (PBS), Benign Frequency Syndrome (BFS), Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

NCT03372720
View directory record Official record
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 9, 2026, 3:17 AM EDT
Not listed Phase 4 Interventional

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

NCT02022722
View directory record Official record
Conditions
Dyspareunia
Interventions
Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride, Pelvic Rehabilitation
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Sep 9, 2026, 3:17 AM EDT
Active, not recruiting No phase listed Observational

Prospective on Market Patient-reported Outcomes for Milli

NCT06397885
View directory record Official record
Conditions
Vaginismus, Dyspareunia
Interventions
Milli Vaginal Dilator
Device
Lead sponsor
Materna Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

NCT01845649
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 9, 2026, 3:17 AM EDT
Withdrawn Not applicable Interventional

Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia

NCT05129332
View directory record Official record
Conditions
Dyspareunia
Interventions
Vaginal Moisturizer, Vaginal Dilator
Other · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Recruiting Not applicable Interventional

VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia

NCT06840314
View directory record Official record
Conditions
Genito-Pelvic Pain/Penetration Disorder, Dyspareunia, Vaginismus, Pelvic Pain, Vestibulodynia, Vulvodynia (Chronic Vulvar Pain)
Interventions
Pelvic floor therapy
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 4 Interventional

A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction

NCT03199534
View directory record Official record
Conditions
Pelvic Pain, Dyspareunia, Pelvic Floor Dysfunction
Interventions
Botulinum toxin A 50u, Botulinum toxin A 100u, Botulinum toxin A 150u
Drug
Lead sponsor
EvergreenHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 4 Interventional

Dilators for Dyspareunia Prevention

NCT01299363
View directory record Official record
Conditions
Post-operative Dyspareunia
Interventions
Dilator use
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 9, 2026, 3:17 AM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Acupuncture for the Treatment of Vulvodynia

NCT02197429
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis, Pain, Dyspareunia, Female Sexual Dysfunction Due to Physical Condition
Interventions
Acupuncture
Other
Lead sponsor
Schlaeger, Judith M., CNM, LAc, PhD
Individual
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Not applicable Interventional

Acupuncture for Vulvodynia: A Pre-pilot Study

NCT02704234
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis, Dyspareunia, Pain
Interventions
Active Acupuncture, Placebo Acupuncture
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Wilmette, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treating Postmenopausal Dyspareunia Where it Hurts

NCT03240081
View directory record Official record
Conditions
Dyspareunia
Interventions
50mcg estradiol cream, 100mcg estradiol cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 9, 2026, 3:17 AM EDT
Suspended Phase 1Phase 2 Interventional

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

NCT01122342
View directory record Official record
Conditions
Vaginitis, Dyspareunia, Breast Neoplasms
Interventions
Testosterone propionate
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

NCT02253173
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Interventions
Estradiol, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Huntsville, Alabama • Montgomery, Alabama • Mesa, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 9, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

NCT04335591
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort

NCT04885556
View directory record Official record
Conditions
Vaginal Discharge, Dyspareunia, Female Sexual Dysfunction, Vaginitis, Bacterial Vaginoses
Interventions
Tampon-like device for absorption of sexual fluids
Device
Lead sponsor
Atlantic Health System
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 9, 2026, 3:17 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial

NCT07260825
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
Interventions
Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 9, 2026, 3:17 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients with Endometriosis.

NCT05540353
View directory record Official record
Conditions
Endometriosis, Dyspareunia, Pelvic Pain
Interventions
Transvaginal photobiomodulation, Sham therapy
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Mitchellville, Maryland • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 9, 2026, 3:17 AM EDT